Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
EveryONE Medicineseomeds.com · Low evidenceEveryONE Medicines is building a scalable platform that connects children with life-threatening neurodegenerative genetic diseases to individualized antisense oligonucleotide (ASO) therapies, matching patients’ variants to a growing library of ASOs or designing custom therapies for new mutations. They are developing a system to speed drug development, regulatory approval, and reimbursement by working with regulators, payers, treatment centers, and diagnostic firms, using AI-enabled sequencing and design to bring an ASO to patients in under 12 months. Their focus is ultra-rare pediatric diseases caused by genetic variants, aiming to make personalized ASO treatments scalable, sustainable, and broadly accessible.
Parse Score